@article{18b0f8ba900f470d822b3b8514137350,
title = "Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia",
abstract = "In Australia, over half of patients with relapsed/refractory chronic lymphocytic leukaemia treated with ibrutinib use concomitant proton pump inhibitors (PPIs). High gastric pH reduces the bioavailability of some Bruton tyrosine kinase inhibitors. There was no difference in duration on ibrutinib with or without concomitant PPI (unadjusted P = 0.61; adjusted hazard ratio: 1.23, 95% confidence interval: 0.75–2.02, P = 0.411). PPI use does not affect ibrutinib treatment persistence.",
keywords = "Australia, Bruton tyrosine kinase (BTK) inhibitors, chronic lymphocytic leukaemia, ibrutinib, proton pump inhibitor (PPI), real-world evidence",
author = "Ross Salvaris and Stephen Mulligan and Andrea Puig and Marija McGeachie and Stephen Opat",
note = "Funding Information: Funding: The study was sponsored by Janssen‐Cilag Pty Ltd Australia. Janssen Biotech, Inc. co‐develops and co‐commercialises ibrutinib in collaboration with Pharmacyclics, Inc. Janssen‐Cilag Pty Ltd Australia contracted Prospection Pty Ltd to perform the analysis. Publisher Copyright: {\textcopyright} 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.",
year = "2023",
month = nov,
doi = "10.1111/imj.16267",
language = "English",
volume = "53",
pages = "2115--2118",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "John Wiley & Sons",
number = "11",
}